Get started
Jaguar Health, Inc.Jaguar Health, Inc.Jaguar Health, Inc.

Jaguar Health, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

JAGX trade ideas

$JAGX entry .52 Target PTs 4-15-35 and higherJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
NASDAQ:JAGXLong
by UnknownUnicorn19246015
1
$JAGX Weekly overviewThe weekly chart looks like a textbook Primary W1 to W2 setup, with a hollow green candle last week from the previous weeks low. The primary wave 3 target here is $8.29, with a final Wave 5 target of $10.46. The weekly RSI is curving up, hoever the momentum has been falling and the stoch RSI is still trending downward, so we could see a slight dip if the overall market is red early this week. This seems likely as a lot of other stocks are showing a similar W1-W2 setup, so a corrective wave could be looming. If we look at the ichimoku cloud however, it has started opening up, so that provides a bit more conviction that, on the longer time frame, we could be heading up. Further more, by overlaying the pitckfork on our EW setup, we can get some estimates for price and time targets. If this setup follows through as expected, i will be looking to buy a pull back around $1.81-1.77 (will likely set my bid at $1.85). We should see around $5.50 by early april, and if this comes to pass it will give us further conviction. I'll be looking for my first sell taget at $8.29, around late april, followed by a consolidation to around $5 by mid may and then a final sell target between $9.80 to $10.40 sometime between late june to late july. TL:DR Buy on pullback at $1.85 this week (March 15-19) PT1 = $8.25 by late april PT2 = $9.80 by late june to late july.
NASDAQ:JAGXLong
by ir-rizzle
20